Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease

Affiliations

• ¹ Department of Pediatrics in the College of Medicine, University of Florida, Gainesville, FL, United States.
• ² Metabolic Unit, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
• ³ Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
• ⁴ Friedrich-Baur-Institute, Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
• ⁵ Erasmus MC University Medical Center, Rotterdam, Netherlands.
• ⁶ M6P-Therapeutics, St Louis, MO, United States.
• ⁷ Amicus Therapeutics, Inc., Princeton, NJ, United States.
• ⁸ Metrum Research Group, Tariffville, CT, United States.
• ⁹ Incyte Corporation, Wilmington, DE, United States.
• ¹⁰ Department of Neurology, University of California, Irvine, Irvine, CA, United States.